Cutler Group LP Syndax Pharmaceuticals Inc Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Jul 19, 2021	SELL	$13.42 - $25.18 $30,866 - $57,914	-2,300 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$19.28 - $24.59 $138,816 - $177,048	-7,200 Reduced 75.79%	2,300 $7,000
Q4 2020 Jan 21, 2021	BUY	$15.1 - $26.44 $143,450 - $251,180	9,500 New	9,500 $4,000
Q1 2020 May 07, 2020	SELL	$6.65 - $12.03 $73,150 - $132,330	-11,000 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$5.43 - $9.22 $59,730 - $101,420	11,000 New	11,000 $0
Q3 2019 Oct 28, 2019	SELL	$7.47 - $10.76 $20,916 - $30,128	-2,800 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$4.9 - $9.31 $9,800 - $18,620	2,000 Added 250.0%	2,800 $3,000
Q1 2019 May 10, 2019	SELL	$4.26 - $6.86 $20,448 - $32,928	-4,800 Reduced 85.71%	800 $0
Q4 2018 Feb 05, 2019	BUY	$3.6 - $8.42 $10,800 - $25,260	3,000 Added 115.38%	5,600 $0
Q3 2018 Nov 07, 2018	BUY	$6.33 - $8.08 $8,862 - $11,312	1,400 Added 116.67%	2,600 $5,000
Q2 2018 Aug 10, 2018	BUY	$6.93 - $14.63 $8,316 - $17,556	1,200 New	1,200 $0

230

90M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.